OmniAb, Inc. announced the presentation of new scientific data on its OmnidAb platform, the industry's first and only transgenic chicken host system producing single domain antibodies (sdAbs), at the 2023 Antibody Engineering & Therapeutics Conference underway in San Diego and hosted by The Antibody Society. The Company presented an overview of OmnidAb and its functionality to industry leaders and prospective customers in a presentation by Christine Vuong, Ph.D., Senior Scientist, titled " Heavy Chain-Only Transgenic Chickens Produce Human Antibodies with Robust Immune Repertoires and High-Affinity Binding." The OmnidAb transgenic chicken novel host system builds upon the success of the Company's OmniChicken legacy by expressing an optimized single-domain human framework that can generate modular building blocks well suited to support a variety of therapeutic modalities. OmnidAb antibodies target distinct epitopes and have favorable developability profiles with high expression levels in mammalian cells.

Compared with traditional antibodies, SDAbs produced by OmnidAb chickens have a compact format that opens new opportunities and broad clinical applications. OmniAb is showcasing OmnidAb and its entire technology stack at the 2023 Antibodies Engineering & Therapeutics Conference at booth #300 at the Marriott Marquis San Diego Marina.